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The in vitro antimicrobial susceptibility of the anaerobic intestinal spirochete Brachyspira pilosicoli was
investigated by an agar dilution method. Human (n  123) and porcine (n  16) isolates were susceptible to
metronidazole, ceftriaxone, meropenem, tetracycline, moxiﬂoxacin, and chloramphenicol; erythromycin and
ciproﬂoxacin were not active. Resistance to amoxicillin and clindamycin varied. Amoxicillin susceptibility was
restored by clavulanic acid.
Brachyspira (previously Serpulina) pilosicoli is an anaerobic
intestinal spirochete which colonizes the large intestines of
pigs, numerous other farmed and wild animals, and humans
(25). In humans, B. pilosicoli is one cause of intestinal spiro-
chetosis, a condition characterized by end-on attachment of
the organism to colorectal epithelial cells (9, 16, 21). In several
reports, intestinal spirochetosis was the only abnormal ﬁnding
for patients with abdominal pain, rectal bleeding, and diarrhea,
and many of these symptoms were long-term or recurrent (4,
12, 16).
B. pilosicoli has been isolated at a prevalence of 10 to 30%
from the feces of a range of different human population groups,
including Aboriginal Australians (3, 15), individuals from de-
veloping countries (2, 3, 23), homosexual males, and human
immunodeﬁciency virus-positive individuals (21). Carriage of
these organisms was associated with gastrointestinal symp-
toms, particularly diarrhea; however B. pilosicoli was also iso-
lated from healthy individuals in these populations. B. pilosicoli
has also been isolated from the bloodstream of individuals in
France, the United States, and Greece (6, 10, 13, 24). All of the
individuals in the latter group were immunocompromised and
suffered other debilitating illnesses, and six subsequently died.
The in vitro susceptibility of B. pilosicoli isolates from hu-
mans has received little attention (20), and currently there are
no approved standards for antimicrobial testing of Brachyspira
species (17). Thus, the aim of this study was to test the in vitro
antimicrobial susceptibility of isolates of B. pilosicoli according
to NCCLS guidelines for testing anaerobes. Human isolates
obtained from a number of geographic locations were tested
together with a small collection of porcine isolates included to
provide comparative data. It was hypothesized that isolates
from different sources would show different patterns of anti-
microbial susceptibility.
(Part of this study was presented at the 6th Biennial Con-
gress of the Anaerobe Society of the Americas, Park City,
Utah, 29 June to 2 July 2002 [C. J. Brooke, T. V. Riley, and
D. J. Hampson, Abstr. 6th Biennial Congr. Anaerobe Soc.
Am., abstr. SP-4, 2002].)
The 139 B. pilosicoli isolates studied included 123 from hu-
mans and 16 from pigs. Human isolates were obtained from
Papua New Guinean (PNG) villagers (n  29) (23), Aborigines
from Western Australian communities (n  32) (3, 15), mi-
grants to Western Australia (n  24) (3), homosexual males
(n  14), and individuals from Oman (n  10) (2) and Italy
(n  7). Seven human isolates from blood samples (6, 24) were
tested also. Porcine isolates were from Australia (n  9),
North America (n  6) (5), and the United Kingdom (the type
strain P43/6/78 [ATCC 51139
T]) (25). All B. pilosicoli isolates
were obtained from the culture collection held at the Refer-
ence Centre for Intestinal Spirochetes at Murdoch University.
The reference organisms for control purposes included the
facultative anaerobes Staphylococcus aureus ATCC 29213, S.
aureus ATCC 25923, and Enterococcus faecalis ATCC 29212,
and the anaerobes Bacteroides fragilis ATCC 25285, Bacte-
roides thetaiotaomicron ATCC 29741, and Clostridium perfrin-
gens ATCC 13124. With the exception of B. thetaiotaomicron,
which was obtained from Judy Holdsworth, Fremantle Hospi-
tal Microbiology Section, the control organisms were obtained
from the Division of Microbiology and Infectious Diseases,
Western Australian Centre for Pathology and Medical Re-
search. All organisms were stored at 70°C in 1% brain heart
infusion broth–10% glycerol–50% horse serum.
The antimicrobial agents tested were amoxicillin (CSL, Park-
ville, Australia), ceftriaxone (Roche Products, Dee Why, Aus-
tralia), chloramphenicol and tetracycline (Sigma Aldrich, Cas-
tle Hill, Australia), ciproﬂoxacin and moxiﬂoxacin (Bayer,
Leverkusen, Germany), clindamycin and gentamicin (Pharma-
cia and Upjohn, Kalamazoo, Mich.), erythromycin (Blaschim,
Milan, Italy), and meropenem (Zeneca, Wilmington, Del.).
The -lactamase inhibitor clavulanic acid (GlaxoSmithKline,
Boronia, Australia) was tested in combination with amoxicillin.
Agents were dissolved in appropriate solvents and stored at
70°C at concentrations of 2,560 or 5,120 g/ml until required.
The antimicrobial susceptibility of B. pilosicoli isolates was
determined by using an agar dilution method based on NCCLS
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Brieﬂy, spirochete stocks were thawed and passaged once on
Colombia base agar with 6% horse blood agar at 37°C for 5
days in an anaerobic chamber (Don Whitley Scientiﬁc, Ltd.,
Shipley, Yorkshire, England) in an atmosphere of 80% N2,
10% H2, and 10% CO2. In preliminary experiments, Wilkins-
Chalgren agar and brucella blood agar for susceptibility testing
(19) did not support the growth of B. pilosicoli. Therefore,
Wilkins-Chalgren agar containing 5% horse serum plus the
appropriate concentration of antimicrobial agent was used.
The agar was made less than 24 h before inoculation and
stored at 4°C until required. The plates containing amoxicillin
were made on the day of use. Facultative control organisms
were inoculated onto Mueller-Hinton agar without horse se-
rum. Growth was resuspended in brucella broth using a sterile
cotton-tipped swab at a concentration of 3  10
7 to 3  10
8
spirochetes/ml, in accordance with McFarland standards. The
suspension was added to the wells of a sterile multipoint inoc-
ulator tray and used to inoculate the agar by means of a Denley
multipoint inoculator (Mast Labs, Liverpool, England), which
delivered 3  10
4 to 3  10
5 organisms per spot. Trays con-
tained the test organisms plus anaerobe controls, while facul-
tative controls were added to another tray and inoculated and
incubated separately. The trays were incubated immediately
after inoculation for 96 h, with anaerobic cultures in the an-
aerobic chamber and facultative controls at 37°C aerobically.
Cultures were compared to a growth control plate contain-
ing no antibiotic, and the MIC of an agent was determined as
the lowest concentration of antimicrobial yielding no growth, a
haze, one discrete colony, or multiple tiny colonies (19). Tests
for each organism were performed at least in triplicate, and the
MIC of each agent was determined as the modal value. An
organism was deﬁned as resistant to a particular agent if the
MIC obtained was above the published breakpoint for anaer-
obic bacteria (17).
As a control for antibacterial activity, and to detect varia-
tions in MICs due to medium-antibiotic interactions, MICs of
agents for anaerobic reference organisms were also deter-
mined in triplicate on the same media under the same test
conditions in accordance with NCCLS standard protocols.
Where an agent did not have published breakpoint values for
anaerobes, aerobic reference organisms inoculated on Muel-
ler-Hinton agar were included for comparison.
-Lactamase production in all strains was assessed by using
BBL Ceﬁnase nitroceﬁn disks (Becton Dickinson). Each disk
was moistened with sterile distilled water, and a loopful of
spirochete growth was smeared onto the disk surface. The disk
was protected from drying and examined for a color change
reaction (from colorless to red) within 10 min and then at 30
min. S. aureus ATCC 29213 and S. aureus ATCC 25923 were
included as positive and negative controls, respectively.
Isolates were categorized on the basis of source, and pro-
portions of resistant isolates and of isolates for which the MICs
were elevated were calculated. Statistical analysis was carried
out using the chi-square or Fisher’s exact test to compare groups.
The numbers of isolates inhibited at various MICs, the MICs
at which 50% of the isolates were inhibited (MIC50s), and the
MIC90s of the 12 antimicrobials tested against B. pilosicoli,
with proportions of isolates susceptible at published break-
points for anaerobic bacteria, are presented in Table 1. In
general, B. pilosicoli isolates were susceptible to the agents
tested, with MIC90s below the breakpoints. Exceptions to this
were amoxicillin and clindamycin, which had MIC90so f6 4a n d
8 g/ml, respectively. Over 50% of the isolates were nitroceﬁn
positive, which, for all except eight isolates, corresponded to an
amoxicillin MIC above the published breakpoint.
A bimodal distribution of MICs was recorded for amoxicil-
lin, erythromycin, and tetracycline but not for clindamycin or
gentamicin. For amoxicillin, the trough in the distribution cor-
responded to the published breakpoint; however, the tetracy-
cline MIC for all isolates was below the breakpoint. Amoxicil-
lin susceptibility was restored by clavulanic acid in all instances
(MIC90,4g/ml), suggesting that -lactamase activity was in-
volved in the initial lack of susceptibility. Similar ﬁndings were
reported by Tompkins et al. (20), who examined 19 spirochete
isolates from Asians and homosexual males living in the
United Kingdom. Activity against penicillin and ampicillin was
demonstrated for four spirochetes (which were almost cer-
tainly B. pilosicoli). Furthermore, the -lactamases were found
to be membrane bound and noninducible.
Based on NCCLS breakpoints for anaerobes, isolates of
B. pilosicoli were susceptible to ceftriaxone, chloramphenicol,
TABLE 1. In vitro activities of 12 antimicrobial agents against 139 B. pilosicoli isolates
Antimicrobial agent
No. of isolates inhibited at MIC (g/ml) of:
MIC50 MIC90 % Sus
a
0.016 0.03 0.06 0.125 0.25 0.5 1 2 4 8 16 32 64 128 256 512 512
Amoxicillin 4 26 34 5 7 5 24 18 12 4 4 64 54.7
Amoxicillin-clavulanic acid
b 4 35 39 35 26 1, 0.5 4, 2 100
Ceftriaxone 19 85 23 11 1 0.25 1 100
Chloramphenicol 4 95 40 1 2 100
Ciproﬂoxacin 4 51 84 4 4 39.6
Clindamycin 3 0 8 13 21 32 23 14 6 8 10 1 0.5 8 86.3
Erythromycin 10182 3 26 60 2 9 2 5 6 512 NA
Gentamicin 3 4 14 48 55 13 2 4 16 NA
Meropenem 16 115 8 0.25 0.25 100
Metronidazole 19 110 10 0.25 0.25 100
Moxiﬂoxacin 4 113 2 2 2 NA
Tetracycline 66 47 0 10 9 7 0.25 2 100
a Sus, susceptible. The following breakpoints for resistance were used: for amoxicillin, 8 g/ml; for amoxicillin-clavulanic acid, 16 and 8 g/ml, respectively; for
ceftriaxone, 64 g/ml; for chloramphenicol, 32 g/ml; for clindamycin, 8 g/ml; for meropenem, 16 g/ml; for metronidazole, 32 g/ml; and for tetracycline,
16 g/ml (17). A breakpoint of 4 g/ml was used for ciproﬂoxacin (18). NA, not available.
b Separate MIC50s and MIC90s are given for amoxicillin and clavulanic acid.
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(MIC90, 512 g/ml) was not active against these organisms.
Breakpoints are currently unavailable for ciproﬂoxacin, which
was included as it is often used to treat diarrheal illness; how-
ever, when a breakpoint of 4 g/ml was used (18), 60% of the
isolates were resistant, which is consistent with the ﬁnding that
the early quinolones are not very active against anaerobes (1).
Moxiﬂoxacin (MIC90,2g/ml) demonstrated better activity,
although its MICs were slightly higher for B. pilosicoli than for
other susceptible anaerobes (7). Clindamycin and erythromy-
cin showed some cross-resistance: the MICs of erythromycin
for all isolates (n  19) resistant to clindamycin were 512
g/ml; however, 10 other isolates for which the erythromycin
MICs were 512 g/ml were not resistant to clindamycin.
Comparisons between the MICs for isolates from the vari-
ous sources are presented in Table 2. The MICs of amoxicillin,
clindamycin, erythromycin, gentamicin, and tetracycline varied
with the source of the isolate. All isolates from PNG villagers
were susceptible to these antibiotics; they also were negative
for -lactamase production. In all instances, proportions of
resistant isolates were signiﬁcantly lower than for other popu-
lation groups (P values were 0.001, except with gentamicin,
with which P was 0.024). The PNG villagers had very basic
living conditions and were originally chosen for study because
of their lack of exposure to antibiotics (22). These isolates may
well represent a naive population of B. pilosicoli.
Signiﬁcantly higher proportions of isolates from Australian
Aboriginals than from other groups were resistant to amoxi-
cillin (P  0.001) or were -lactamase producers (P  0.001).
However, for signiﬁcantly lower proportions of these isolates,
the MICs of gentamicin (P  0.015) and tetracycline (P 
0.021) were raised. The high proportions of -lactamase pro-
duction most likely reﬂected exposure of this group to antibio-
tics. Respiratory disease and otitis media are signiﬁcant health
problems in the Aboriginal Australian population (14, 26).
Pneumococci are the biggest cause of pneumonia and otitis
media in this population, and recommended therapies are pen-
icillin G and amoxicillin, respectively (8, 26).
Tetracycline MICs for over 85% of isolates from homosex-
ual males were elevated (P  0.001), but these isolates were
not resistant to tetracycline as assessed with NCCLS break-
points. This phenomenon was also recorded by Tompkins and
colleagues for isolates from three homosexual males (20). The
proportions of isolates for which the tetracycline MICs were
elevated were also signiﬁcantly higher for pigs (P  0.013).The
MICs of all ﬁve antibiotics for the porcine isolates were raised,
and those of clindamycin (P  0.046), erythromycin (P 
0.025), and gentamicin (P  0.001), as well as tetracycline,
were signiﬁcantly higher. All groups except those from PNG
and Oman contained isolates for which the MICs of three or
more antibiotics were elevated; the MICs for isolates only from
pigs (P  0.013) and homosexual males (P  0.006) were
signiﬁcantly higher, while those for isolates from PNG villagers
(P  0.0062) were signiﬁcantly lower.
The higher MICs of -lactam and lincosamide antibiotics for
pig isolates may be due to the use of antibiotics as growth
promoters and therapeutic agents in veterinary settings. The
prominent use in swine farming of tylosin, another macrolide,
and lincomycin, another lincosamide, has led to reports of a
high frequency of resistance of intestinal spirochetes to these
antibiotics (11). Penicillins are also used frequently as therapy
for other swine infections. Gentamicin MICs were raised only
for isolates from pigs. For pig isolates, Duhamel et al. (5) rec-
ommended gentamicin breakpoints of  1 g/ml as suscepti-
ble, 5 g/ml as intermediate, and 10 g/ml as resistant; how-
ever, the bimodal distribution they described was not seen in
the present study.
Previous studies of the antimicrobial susceptibility of intes-
tinal spirochetes have tended not to adhere to standard meth-
ods. Although agar dilution susceptibility methods have used
Trypticase soy agar, parameters such as inoculum concentra-
tion, duration of incubation, and criteria for determination
of MIC have differed. Reproducible susceptibility testing of
Brachyspira hyodysenteriae isolates has been achieved by broth
microdilution with brain heart infusion broth plus 10% fetal
calf serum and specialized microplates (11); however, these are
manufactured in Sweden and are not commercially available.
In addition, the methods still do not conform to NCCLS rec-
ommendations.
The results obtained in this study indicate that antimicrobial
susceptibility testing of B. pilosicoli is possible by the NCCLS
agar dilution method. The only modiﬁcations made were the
addition of 5% horse serum to the Wilkins-Chalgren agar, a
recommendation supported by the Wadsworth Anaerobic Bac-
TABLE 2. Percentages of B. pilosicoli isolates which were nitroceﬁn positive and resistant to amoxicillin and clindamycin and for which
the MICs of erythromycin, gentamicin, tetracycline, and three or more of these ﬁve antimicrobials were raised
Source No. of
isolates
















Aboriginal Australians 32 93.8* 81.3* 12.5 28.1 0.0† 3.1† 12.5
Migrants to WA
b 24 58.3 45.8 12.5 20.8 4.2 4.2† 4.2
Homosexual males 14 50.0 50.0 28.6 35.7 21.4 85.7* 42.9*
Omani nationals 10 60.0 60.0 0.0 0.0 10.0 0.0 0.0
Blood isolates 7 28.6 14.3 42.9 42.9 28.6 42.9 28.6
Italian patients 7 28.6 28.6 0.0 0.0 14.3 28.6 14.3
PNG villagers 29 0.0† 0.0† 0.0† 0.0† 0.0† 0.0† 0.0†
Swine 16 62.5 62.5 31.3* 43.8* 43.8* 43.8* 37.5*
Total 139 51.1 45.3 13.7 20.9 10.8 18.7 15.1
a  Denotes percentage values which are signiﬁcantly higher than the percentage obtained for all isolates; † denotes percentage values which are signiﬁcantly lower
than the percentage obtained for all isolates.
b WA, Western Australia.
2356 NOTES ANTIMICROB.A GENTS CHEMOTHER.teriology Manual (19), and an increase in the incubation time
for these slowly growing organisms. The addition of horse
serum permitted consistent growth of all isolates tested while
allowing reference anaerobes to remain within their accepted
susceptibility ranges. The method was highly reproducible and
easily adapted for testing B. pilosicoli and may be suitable for
testing other Brachyspira spp. The data generated in this study
may be useful in selecting a therapeutic regimen for infections
with B. pilosicoli.
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